secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001193125-24-262543
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences raises $53M in oversubscribed private placement for FB102 clinical development
--------------------------------------------------------------------------------

- Gross proceeds ~$53M from shares and pre-funded warrants to institutional investors including OrbiMed, Janus Henderson, Tybourne.
- Private placement expected to close November 21, 2024; net proceeds for working capital and general corporate purposes.
- FB102 healthy volunteer study completed; celiac disease trial topline readout projected Q2 2025.
- Additional indications expected over next 12 months; R&D Day on December 3, 2024.
- CEO Paul Wagner says financing is transformative and well capitalized for continued advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524262543/0001193125-24-262543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524262543/d815860d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-262543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer